SEC Tracker
Get the app

Outlook Therapeutics OTLK

Outlook Therapeutics FY 2024: net loss $75.4M; diluted EPS −$4.06

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Outlook Therapeutics reported for the year ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$75.4MAgainst −$59.0M in FY 202310-K income statement, on EDGAR
  2. Diluted EPS−$4.06Against −$4.80 in FY 202310-K income statement, on EDGAR
  3. Cash and cash equivalents$14.9M−36% from $23.4M in FY 202310-K balance sheet, on EDGAR
  4. Cash from operations−$68.8MAgainst −$43.0M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Outlook Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. OnKure Therapeutics OKUR public float $28M, Jun 30, 2025
  2. Palatin Technologies PTN public float $26M, Dec 31, 2025
  3. Scynexis SCYX public float $26M, Jun 30, 2025
  4. Champions Oncology CSBR public float $29M, Oct 31, 2025
  5. Rockwell Medical RMTI public float $29M, Jun 30, 2025